Retrospective Assessment of a Serum Proteomic Test in a Phase III Study Comparing Erlotinib plus Placebo with Erlotinib plus Tivantinib (MARQUEE) in Previously Treated Patients with Advanced Non‐Small Cell Lung Cancer

BACKGROUND. The VeriStrat test provides accurate predictions of outcomes in all lines of therapy for patients with non‐small cell lung cancer (NSCLC). We investigated the predictive and prognostic role of VeriStrat in patients enrolled on the MARQUEE phase III trial of tivantinib plus erlotinib (T+E...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Oncologist
Autori principali: Buttigliero, Consuelo, Shepherd, Frances A., Barlesi, Fabrice, Schwartz, Brian, Orlov, Sergey, Favaretto, Adolfo G., Santoro, Armando, Hirsh, Vera, Ramlau, Rodryg, Blackler, Adele R., Roder, Joanna, Spigel, David, Novello, Silvia, Akerley, Wallace, Scagliotti, Giorgio V.
Natura: Artigo
Lingua:Inglês
Pubblicazione: John Wiley & Sons, Inc. 2018
Soggetti:
European Perspectives
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6656491/
https://ncbi.nlm.nih.gov/pubmed/30139835
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0089
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi